Board & Advisors
A highly experienced Board Member and Chairman and Harvard Business School Graduate with a current portfolio including non-executive and executive advisory roles with a range of professional services, Government, and private entrepreneurial organisations.
Strong cross-border, cultural stakeholder with renowned matrix experience and management skills. Recognised as a problem solver and strategic thinker. Successful negotiator and strategist. Acknowledged effective change management and team leader.
An accomplished and senior life science’s professional advisor with over 30 years’ experience deploying significant expertise in taking early-stage companies forward through to commercial maturity.
Appointed to numerous Chairman, Board and CEO positions in start-up companies through to NASDAQ listings. Provided significant commercialisation and commercial advancement contributions to the health care industry. Such contributions have included providing expert advisory to pharma, diagnostics and life sciences companies. Previous engagements include Novartis Diagnostics, EPIX Pharmaceuticals, Tyrogenex and Booz, Allen & Hamilton.
Dr David Wood
Accomplished, creative, and results-oriented life sciences corporate development and strategy executive with 15 years of experience advising management teams and boards of directors on growth strategies. Extensive experience and network in the Diagnostics and Drug Discovery Tools industries having worked with a range of companies evaluating strategies for organic/inorganic growth, financing, and development/commercial partnerships; as well as executing numerous M&A, equity financings, and partnering transactions to help realize these strategies.
Analytical and strategic thinker combining strong scientific understanding, deep knowledge of markets, and excellent business acumen honed by a diverse career in corporate development, investment banking, and equity research.
Steve is an NCI (National Cancer Institute) trained academic medical oncologist.
He has 35+ years oncology drug development experience and 10+ years biomarker and drug-diagnostic co-development. He has led multiple drug and companion diagnostic approvals in US and other major markets.
Steve has also driven technical and clinical business development due diligence and alliance partnerships.
He is a strategic builder and leader of clinical research and translational medicine organizations.